Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01325142 · ClinicalTrials.gov registry record
Genetic Risk of Osteonecrosis of the Jaw (ONJ) in Patients With Metastatic Cancer
A clinical trial of Osteonecrosis and Metastases, sponsored by University of Michigan.
- Completed
- Registry status
- 271
- Enrollment target
- 1
- Study location
NCT01325142: Completed study of Osteonecrosis and Metastases, sponsored by University of Michigan.
NCT01325142 is a study of Osteonecrosis and Metastases that has completed, run by University of Michigan. The registered enrollment target is 271 participants, below the 2,884-participant average among 7 other Osteonecrosis trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01325142, a study of Osteonecrosis and Metastases, has completed, sponsored by University of Michigan.
- COMPLETED
- Registry status
- 271 participants
- Enrollment target
- 1
- Study location
Study Summary
This study seeks to identify risk factors associated with the development of a jaw condition seen in patients with cancer treated with certain medications.
Primary Outcome
analysis is ongoing
Conditions Studied
Study Locations (1)
Michigan
- University of Michigan - Ann Arbor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 271 participants |
| Start Date | 2010-08 |
| Est. Completion | 2014-11 |
What the finished NCT01325142 record still lists
NCT01325142 is an observational study that tracks outcomes without assigning an intervention. The registered 271 participants enrollment target is mid-sized for trials with a published cap, below the 2,884-participant average among 7 other Osteonecrosis trials with a reported enrollment target (91% lower).
The record links to 4 conditions, with Osteonecrosis appearing as the primary indexed condition, and to 0 interventions.
NCT01325142 reports a single indexed study location in Michigan.
Frequently Asked Questions
What is clinical trial NCT01325142 about?
NCT01325142 is a clinical study titled "Genetic Risk of Osteonecrosis of the Jaw (ONJ) in Patients With Metastatic Cancer". This study seeks to identify risk factors associated with the development of a jaw condition seen in patients with cancer treated with certain medications.
What is the current status of trial NCT01325142?
This trial is currently completed. The enrollment target is 271 participants. The study started on 2010-08. Estimated completion is 2014-11.
What conditions does trial NCT01325142 study?
This clinical trial studies the following conditions: Osteonecrosis, Metastases, Bone Diseases, Bisphosphonate-Associated Osteonecrosis of the Jaw.
Who is sponsoring clinical trial NCT01325142?
This trial is sponsored by University of Michigan, which has 1,327 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01325142 being conducted?
This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Osteonecrosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Alendronate for Osteonecrosis in Adults With Sickle Cell Disease
RECRUITING · Phase 2
-
Early Feasibility Study of Cartilage Defect Repair
RECRUITING · NA
-
Exactech Shoulder Post Market Clinical Follow-up Study
RECRUITING
-
Sickle Cell Disease (SCD) Bone Pain Study
ACTIVE NOT RECRUITING · NA
-
The Use of Genex in the Management of Early-Stage Osteonecrosis of the Femoral Head
ACTIVE NOT RECRUITING
-
Imaging of Osteonecrosis With Ferumoxytol-Enhanced MRI
COMPLETED · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03609216 · 271 participants · Phase 2
Gemcitabine and Cisplatin Without Cystectomy for Patients With Muscle Invasive Bladder Urothelial Cancer and Select Genetic Alterations
- NCT02468024 · 272 participants · Phase 3
JoLT-Ca Sublobar Resection (SR) Versus Stereotactic Ablative Radiotherapy (SAbR) for Lung Cancer
- NCT05519449 · 272 participants · Phase 1
Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)
- NCT06035939 · 272 participants · NA
SMYLS Multi-site Trial
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia